Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
MART-1 peptide-pulsed dendritic cell vaccine
- Development stage
- Unknown
- Lead developer
- University of Texas MD Anderson Cancer Center
- Modality
- Dendritic Cell Vaccines → Immune Effector Cells → Other Cell Types → Cell Therapies, Vaccines & Immunotherapeutics
- Administration
- Intravenous
01
Overview
MART-1 peptide-pulsed dendritic cell vaccine is an autologous cellular immunotherapy developed by M.D. Anderson Cancer Center for the treatment of metastatic melanoma. The therapy involves harvesting a patient's own dendritic cells and pulsing them with MART-1 (Melanoma Antigen Recognized by T cells 1) peptides to enhance their ability to present tumor antigens. These matured dendritic cells are administered intravenously to stimulate and sustain the anti-tumor activity of adoptively transferred tumor-infiltrating lymphocytes (TILs). This approach is typically used in a regimen following lymphodepletion with cyclophosphamide and fludarabine, and is accompanied by high-dose interleukin-2 (IL-2) to promote T-cell expansion and persistence in vivo. The treatment is specifically designed to enhance the immune system's ability to recognize and destroy melanoma cells by providing potent antigen presentation.
- Other names
- Dendritic Cell ImmunizationMART-1 peptide-pulsed Dendritic CellsMART1 peptide-pulsed Dendritic CellsMART 1 peptide-pulsed Dendritic Cellsdendritic cell immunization-M.D. Anderson Cancer Center-melanoma
02
Targets
MLANA (Melanoma antigen recognized by T cells 1)HLA-A*02 (Human leukocyte antigen A*02 complexed peptide)
Beyond the preview
Go deeper on MART-1 peptide-pulsed dendritic cell vaccine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on MART-1 peptide-pulsed dendritic cell vaccine.